




RealRate

PHARMACEUTICAL 2014

Traverse Therapeutics Inc
Rank 221 of 234



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Traverse Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Traverse Therapeutics Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 30% points. The greatest weakness of Traverse Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 91% points.

The company's Economic Capital Ratio, given in the ranking table, is 49%, being 194% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	7,501
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	35,210
Liabilities, Non-Current	0
Other Assets	12,870
Other Compr. Net Income	-110
Other Expenses	9,851
Other Liabilities	3,601
Other Net Income	-33,748
Other Revenues	0
Property and Equipment	127
Research and Development	7,084
Selling, General and Administrative Expense	16,888

Output Variable	Value in 1000 USD
Assets	20,499
Liabilities	38,811
Expenses	33,824
Revenues	0
Stockholders Equity	-18,312
Net Income	-67,571
Comprehensive Net Income	-67,626
BaseVar	63,495
ECR before Limited Liability	-363%
Economic Capital Ratio	49%